DocGo (NASDAQ:DCGO) Given New $7.00 Price Target at BTIG Research

DocGo (NASDAQ:DCGO) had its price target reduced by research analysts at BTIG Research from $11.00 to $7.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 127.27% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC reduced their price objective on shares of DocGo from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday. Canaccord Genuity Group decreased their target price on DocGo from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, April 11th. Stifel Nicolaus cut their price target on DocGo from $8.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Finally, Cantor Fitzgerald reduced their price objective on DocGo from $11.00 to $5.00 and set an “overweight” rating for the company in a research note on Thursday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $7.75.

DocGo Price Performance

Shares of DCGO stock traded down $0.42 on Thursday, reaching $3.08. 1,983,636 shares of the stock were exchanged, compared to its average volume of 1,452,829. The stock has a 50 day moving average price of $3.70 and a 200 day moving average price of $4.42. The stock has a market cap of $320.85 million, a PE ratio of 43.86, a P/E/G ratio of 0.41 and a beta of 0.96. DocGo has a one year low of $2.78 and a one year high of $10.82.

DocGo (NASDAQ:DCGO) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.07). The firm had revenue of $199.25 million during the quarter, compared to the consensus estimate of $195.48 million. DocGo had a net margin of 1.10% and a return on equity of 2.01%. On average, research analysts expect that DocGo will post 0.31 earnings per share for the current fiscal year.

Insider Transactions at DocGo

In other news, Director Michael J. Burdiek bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was bought at an average price of $3.61 per share, for a total transaction of $36,100.00. Following the transaction, the director now directly owns 571,595 shares of the company’s stock, valued at approximately $2,063,457.95. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 13.78% of the company’s stock.

Institutional Investors Weigh In On DocGo

Large investors have recently made changes to their positions in the business. AJOVista LLC bought a new position in DocGo in the 4th quarter worth about $25,000. Victory Capital Management Inc. purchased a new position in shares of DocGo during the 3rd quarter valued at $55,000. Cape Investment Advisory Inc. bought a new stake in DocGo during the 4th quarter valued at approximately $63,000. Verdence Capital Advisors LLC purchased a new position in shares of DocGo during the first quarter valued at about $64,000. Finally, Envestnet Portfolio Solutions Inc. bought a new position in DocGo during the third quarter valued at $67,000. 56.44% of the stock is currently owned by institutional investors.

DocGo Company Profile

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.